Search the Newsreel

How Securities Lawsuits Over Trial Disclosures Will Impact Regeneron Pharmaceuticals’ (REGN) Pipeline-Driven Investment Story

Regeneron Pharmaceuticals is facing securities class action lawsuits concerning alleged misleading statements about its Phase III Fianlimab-Libtayo trial. These lawsuits, focusing on disclosure practices regarding trial delays and failure, could influence investor perception of Regeneron's pipeline-driven strategy, especially as the company advances new programs …

Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy

Wall Street Zen has upgraded Regeneron Pharmaceuticals (NASDAQ:REGN) from a "buy" to a "strong-buy" rating. This upgrade follows Regeneron's strong quarterly earnings, where it surpassed analyst expectations for both EPS and revenue. Despite positive news regarding pipeline expansion and collaborations, the company faces risks …

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron's cemiplimab (Libtayo) in patients with solid tumors. …

Bernstein Lifts Regeneron Price Target to $756, Stays on Sidelines

Bernstein has raised its price target for Regeneron Pharmaceuticals to $756 from $753, while maintaining a Market Perform rating, indicating a slightly more positive near-term outlook but not a fundamental shift in its investment thesis. This new target remains below the Wall Street consensus …

Bernstein Adjusts PT on Regeneron Pharmaceuticals to $756 From $753, Maintains Market Perform Rating

Bernstein has increased its price target for Regeneron Pharmaceuticals (REGN) to $756 from $753, while maintaining a "Market Perform" rating on the stock. This adjustment reflects a modest change in the analyst's valuation, indicating a continued neutral stance on the company's stock performance. The …

Alnylam Pharmaceuticals (ALNY) Cuts Guidance As Undervalued Narrative Faces A Tougher Test

Alnylam Pharmaceuticals (ALNY) recently cut its full-year 2026 TTR product sales guidance by $200 million and is under a securities law investigation, leading to significant share price pressure. Despite a "most popular narrative" suggesting the stock is 47.8% undervalued with a fair value of …

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Regeneron Pharmaceuticals Inc. (REGN) saw its stock price rally by 1.00% to $805.97, outperforming its competitors and the broader market on a strong trading day. This marked the stock's second consecutive day of gains, with the S&P 500 Index and Dow Jones Industrial Average …

REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt

A class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo Study, leading to …

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is reminding investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (REGN) for alleged securities fraud. The lawsuit claims Regeneron made false and misleading statements regarding its Phase III Fianlimab-Libtayo Study, which supposedly failed to demonstrate clinical differentiation. Investors …

Telix Pharmaceuticals (ASX:TLX) Posts US$247M Quarter and Targets Over US$1B 2026 Revenue Plus Other Income

Telix Pharmaceuticals reported its strongest quarterly revenue to date, reaching US$247 million in Q2 2026, driven by its Precision Medicine division. The company projects its total 2026 revenue plus other income to exceed US$1 billion, bolstered by a US$40 million payment from a new …

Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $640,000.00 in Stock

Regeneron Pharmaceuticals director Huda Zoghbi sold 800 shares of the company's stock for $640,000, reducing her direct ownership by nearly 32%. This transaction occurred under a pre-arranged Rule 10b5-1 trading plan. The sale comes as Regeneron reported strong quarterly earnings with revenue up 16.7% …

REGN Stockholders May Be Entitled to Lead the Class Action Lawsuit Against Regeneron Pharmaceuticals, Inc. - Contact Robbins LLP for Information About Becoming the Lead Plaintiff

Robbins LLP is reminding investors who purchased Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025, and May 15, 2026, about a securities class action lawsuit. The lawsuit alleges that Regeneron misled investors regarding its Phase 3 Fianlimab-Libtayo clinical trial for advanced melanoma, …

Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP

Hagens Berman Sobol Shapiro LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals (NASDAQ: REGN) on behalf of investors who suffered substantial losses. The lawsuit stems from surprising revelations about a failed Phase 3 clinical trial for a melanoma therapy, which caused …

REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE

Bernstein Liebhard LLP reminds investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) with losses that they have until September 14, 2026, to join a securities class action lawsuit. The lawsuit alleges that Regeneron made false and misleading statements between August 1, 2025, and May 15, …

Regeneron Pharmaceuticals, Inc. Notice of September 14,

Hagens Berman Sobol Shapiro LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals (NASDAQ: REGN) on behalf of investors who purchased shares between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made misleading statements regarding a failed Phase …

Better Value & Growth: INCY, HALO Top Regeneron Pharmaceuticals Stock

Insight Wealth Strategies LLC Has $5.46 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Insight Wealth Strategies LLC increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 26.9% in the second quarter, bringing its total holdings to $5.46 million. Regeneron reported strong quarterly results with significant revenue growth and beat EPS estimates, maintaining a "Moderate Buy" consensus rating from …

Regeneron, Tenet leads top healthcare companies with highest earnings beats (XLV:NYSEARCA)

Regeneron Pharmaceuticals and Tenet Healthcare lead the healthcare sector with the highest positive earnings per share surprises, according to an analysis of corporate earnings. Other companies with significant beats include Eli Lilly, Biogen, and UnitedHealth. While positive EPS surprises indicate operational resilience and exceeding …

How Regeneron Pharmaceuticals Went From Cheaper Than Incyte To The Pricier Stock

Regeneron Pharmaceuticals (REGN) now trades at a premium compared to Incyte (INCY), a reversal from a year ago. Regeneron's premium is attributed to its scale, blockbuster drugs like Dupixent and EYLEA HD, and a deep pipeline of approximately 50 clinical programs, despite slower growth …

Handelsbanken Fonder AB Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Handelsbanken Fonder AB significantly reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 58.1% in the second quarter, selling 72,708 shares and leaving them with 52,328 shares valued at $32,629,000. This move comes as other institutional investors have both increased and decreased their holdings in …

Regeneron Pharmaceuticals Inc (REGN) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors

Regeneron Pharmaceuticals Inc. (REGN) stock fell by 1.37% to $797.00 on Tuesday, breaking a five-day winning streak. This underperformance occurred during a generally poor trading session, with the S&P 500 Index and Dow Jones Industrial Average also experiencing declines.

Regeneron Pharmaceuticals (REGN) Following Earnings And Buybacks, Is The Valuation Case Still Intact?

Regeneron Pharmaceuticals (REGN) has garnered investor attention after releasing its Q2 and six-month 2026 results, affirming a dividend, and detailing recent share repurchases. While the company's broad pipeline supports future revenue growth and analysts view it as 3% undervalued with a fair value of …

REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?

The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index …

REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit

Hagens Berman Sobol Shapiro LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals (NASDAQ: REGN) after a Phase 3 clinical trial for a melanoma treatment failed, causing an $11 billion market cap wipeout. The lawsuit alleges that Regeneron made misleading statements and …

REGN DEADLINE: The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline

The Gross Law Firm is reminding investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) about an upcoming securities class action deadline of September 14, 2026. The lawsuit alleges that Regeneron made false and misleading statements regarding its Phase III Fianlimab-Libtayo Study, leading to significant stock …

NewEdge Advisors LLC Has $5.88 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

NewEdge Advisors LLC recently reduced its stake in Regeneron Pharmaceuticals, Inc. by 23.3% in the first quarter, now holding 7,610 shares valued at $5.88 million. Despite this, institutional investors collectively own a significant 83.31% of the company's stock. Regeneron reported strong quarterly earnings of …

¿4% Infravalorada? Regeneron Pharmaceuticals (REGN) Tras Sus Resultados Y Recompras

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Regeneron Pharmaceuticals (NASDAQ:REGN) has received a consensus "Moderate Buy" rating from analysts, with 16 recommending buy, 10 hold, and one strong-buy. The company recently surpassed quarterly earnings and revenue expectations, reporting $14.29 EPS against an estimated $10.16 and $4.29 billion in revenue, a 16.7% …

REGENERON PHARMACEUTICALS, INC. SEC Filing (Aug 10, 2026)

This article details a Form 144 SEC filing by Regeneron Pharmaceuticals, Inc. (REGN) on August 10, 2026. The filing indicates a proposed sale of 800 shares of common stock acquired through the exercise of stock options on the same day, with an aggregate market …

Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: Navigating Biotech Opportunities with a 6.27% Upside Potential

Regeneron Pharmaceuticals, Inc. (REGN), a major biotechnology firm with an $80.75 billion market cap, shows a 6.27% upside potential according to analysts. The company exhibits robust financial health with 16.70% revenue growth and over $3 billion in free cash flow, supported by strategic partnerships …

Contravisory Investment Management Inc. Purchases Shares of 10,147 Regeneron Pharmaceuticals, Inc. $REGN

Contravisory Investment Management Inc. acquired 10,147 shares of Regeneron Pharmaceuticals (NASDAQ:REGN) valued at approximately $6.3 million during the second quarter. Regeneron reported strong quarterly earnings, surpassing analyst estimates with $14.29 EPS and $4.29 billion in revenue, and declared a quarterly dividend of $0.94 per …

REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

Faruqi & Faruqi, LLP is reminding investors of Regeneron (NASDAQ:REGN) about an upcoming September 14, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo Study, which …